Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHA 2015

11–14 June 2015 | Reed Messe, Vienna, Austria

EHA 2015

11–14 June 2015 | Reed Messe, Vienna, Austria
ELOQUENT-2 trial of elotuzumab plus lenalidomide/dexamethasone in multiple myeloma 1:41
ELOQUENT-2 trial of elotuzumab plus lenalidomide/dexamethasone in multiple myeloma
Sagar Lonial • 2 Jun 2015
An overview of daratumumab monotherapy for heavily treated multiple myeloma 1:08
An overview of daratumumab monotherapy for heavily treated multiple myeloma
Sagar Lonial • 2 Jun 2015
Phase 2 study of daratumumab monotherapy for heavily pretreated and refractory multiple myeloma 1:47
Phase 2 study of daratumumab monotherapy for heavily pretreated and refractory multiple myeloma
Jesús San Miguel • 12 Jun 2015
Clinical trials of non-chemotherapy-containing therapies by the German CLL Study Group 2:36
Clinical trials of non-chemotherapy-containing therapies by the German CLL Study Group
Barbara Eichhorst • 12 Jun 2015
Defining therapeutic strategies in elderly acute myeloid leukemia 5:53
Defining therapeutic strategies in elderly acute myeloid leukemia
Charles Craddock • 12 Jun 2015
OS after adjustment for crossover in a study of idelalisib with rituximab for relapsed CLL 1:25
OS after adjustment for crossover in a study of idelalisib with rituximab for relapsed CLL
Paolo Ghia • 12 Jun 2015
Unmet clinical needs in multiple myeloma 1:23
Unmet clinical needs in multiple myeloma
Pieter Sonneveld • 12 Jun 2015
Exploring the potential of T-cell therapy for acute lymphoblastic leukemia 4:44
Exploring the potential of T-cell therapy for acute lymphoblastic leukemia
Dieter Hoelzer • 12 Jun 2015
SABRINA trial: Subcutaneous versus intravenous rituximab for follicular lymphoma 1:33
SABRINA trial: Subcutaneous versus intravenous rituximab for follicular lymphoma
Andrew Davies • 12 Jun 2015
SPRINT trial: Lenalidomide for relapsed/refractory mantle cell lymphoma 2:58
SPRINT trial: Lenalidomide for relapsed/refractory mantle cell lymphoma
Marek Trněný • 12 Jun 2015
A review of the treatment evolution in relapsed/refractory multiple myeloma 5:46
A review of the treatment evolution in relapsed/refractory multiple myeloma
Paul Richardson • 12 Jun 2015
HELIOS trial: Ibrutinib combined with BR for previously treated CLL/SLL 5:29
HELIOS trial: Ibrutinib combined with BR for previously treated CLL/SLL
Paula Cramer • 13 Jun 2015
FIRST trial: Continuous lenalidomide plus dexamethasone for newly diagnosed multiple myeloma 2:54
FIRST trial: Continuous lenalidomide plus dexamethasone for newly diagnosed multiple myeloma
Thierry Facon • 11 Jun 2015
New era for monoclonal antibody-based immunotherapy for treating multiple myeloma 3:53
New era for monoclonal antibody-based immunotherapy for treating multiple myeloma
Sagar Lonial • 11 Jun 2015
Treating mantle cell lymphoma earlier in the disease course 2:17
Treating mantle cell lymphoma earlier in the disease course
Marek Trněný • 12 Jun 2015
Data on new therapeutic strategies in Hodgkin lymphoma 2:43
Data on new therapeutic strategies in Hodgkin lymphoma
Andrew Davies • 12 Jun 2015
The content of VJHemOnc is intended for healthcare professionals